Can-Fite BioPharma (CANF) Price to Sales (2016 - 2023)

Can-Fite BioPharma (CANF) has 8 years of Price to Sales data on file, last reported at 2013.22 in Q4 2023.

• For the quarter ending Q4 2023, Price to Sales fell 39.88% year-over-year to 2013.22; the trailing twelve-month figure through Dec 2023 stood at 2013.22 (down 39.88% YoY), and the FY2025 full-year result was 8.13, down 99.69% from the prior year.
• Price to Sales was 2013.22 for Q4 2023 at Can-Fite BioPharma, up from 1505.38 in the prior quarter.
• In the past five years, Price to Sales ranged from a high of 6208.11 in Q1 2021 to a low of 161.33 in Q2 2019.
• A 5-year average of 2399.18 and a median of 2013.22 in 2023 frame the typical range for Price to Sales.
• Across the five-year window, Price to Sales tumbled 91.49% in 2019 and surged 1126.02% in 2021, its largest moves.
• Can-Fite BioPharma's Price to Sales stood at 697.59 in 2019, then soared by 504.05% to 4213.82 in 2020, then dropped by 0.75% to 4182.14 in 2021, then declined by 19.93% to 3348.62 in 2022, then plunged by 39.88% to 2013.22 in 2023.
• Per Business Quant data, the three most recent Price to Sales figures were 2013.22 in Q4 2023, 1505.38 in Q3 2023, and 1724.75 in Q2 2023.